Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
about
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumoursReview on molecular and chemopreventive potential of nimbolide in cancerPathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsMeta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.Risk of breast cancer recurrence associated with carbohydrate intake and tissue expression of IGFI receptorPositive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancerEvolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapyAssociation between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer.Loss of Akt1 or Akt2 delays mammary tumor onset and suppresses tumor growth rate in MTB-IGFIR transgenic mice.Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarraysThe potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis.Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage DifferentiationuPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.Repurposing L-Menthol for Systems Medicine and Cancer Therapeutics? L-Menthol Induces Apoptosis through Caspase 10 and by Suppressing HSP90Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases.Impact of heat-shock protein 90 on cancer metastasisIGF-1 receptor inhibitors in clinical trials--early lessonsA multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease.Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231).Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceInsulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.Integrative analysis of cancer-related signaling pathways.Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance.Expression of insulin-like growth factor 2 in mesenchymal neoplasms.Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis.Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor.Insulin-like growth factor-1 receptor is associated with better prognosis in classical Hodgkin's lymphoma: Correlation with MET expression.Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ.
P2860
Q24813725-0AEC1E7E-D59D-4397-88B4-5B219A57042AQ28082973-BA64A1EA-A7A5-409E-8FDE-D0A4698FB192Q28265304-1BCFE7A5-8FEB-4417-917B-07AE3A143659Q33338630-E45B28EE-341D-4A5C-966A-B76947E74E2FQ33847983-A642942D-C695-434D-944B-541EEA6582F4Q33875800-20793535-12BA-41BD-BD52-AC757A5668EBQ34023653-A32EA607-FEB5-4342-B50A-1B40D45A5AFEQ34515619-1D8F0216-D246-4AE9-9DCE-C10AC05A959EQ34898828-7D87F729-48E0-47E9-A45C-B89E87A1F67BQ35000680-93F0858E-011B-4EA4-9877-8A0A098BDB0AQ35037251-364217D1-B277-48CE-9F53-BA6128082F05Q35063782-4893A962-3CC7-4ECC-BA66-331EA95F8AA9Q35123145-34873034-C9D5-4F40-9B68-C9D3B3E88AC9Q35535296-2231A225-2545-479F-8564-7E01E5BCD3FBQ36097941-4220D22A-21E6-4802-8748-FBBF39175114Q36538573-38BB0AE9-321C-4DC9-89A1-3A8809BBBB97Q36790876-8D5CD811-C05D-44FD-B1F9-EBE84F9CD3CEQ37080957-FE122B79-59A2-4931-BA5D-8B0BD0785BCAQ37272247-E16D0019-7BC0-4FF0-9506-507C1D820E2BQ37309022-C8E158C2-D2EB-4B56-A3A6-5BAC2B2BD72FQ37396281-78568B94-1D46-4DC5-857D-72A603E4D6F3Q37775105-ECB1369A-A390-476B-A5AF-AE079FC075DEQ38302045-02C96D66-ADB6-4D3A-9295-1412AAEAEBCFQ38436359-FAC15D70-E57D-4122-BAE4-C2059A518D77Q38989156-5280DE91-33CB-4C1B-A19A-ED2E3AD122A5Q39250672-46933934-F282-403D-BF2B-DCA059F8A42EQ39960713-1559FE44-AC2D-4134-99E5-6118078F9957Q40431244-692EF610-B024-4CA6-B36C-531982DBA568Q41458214-C67F0B3D-0580-4FCF-AF5B-23E8738C0396Q42579657-6A6090EE-4657-467F-981C-F7A7FB972B3EQ43887658-9A04743E-AE56-46D6-98C4-E0A0E51F4F22Q47945526-79AFB75F-7DE4-4C91-9486-EA4A280AA42EQ51531354-2F42F9B8-C5DF-49AF-9C5A-B16E7BCB67C0Q53232395-DFF56640-8699-4FAD-9DAF-6AEB92411866Q53525637-2EF46753-9A3F-4201-84B8-0FA6A2E9D5FEQ54638432-382C05F7-3101-4E67-9DC8-1CE84A4F2D5C
P2860
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@ast
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@en
type
label
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@ast
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@en
prefLabel
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@ast
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@en
P2093
P1433
P1476
Expression of the insulin-like ...... th 17-allylamino geldanamycin.
@en
P2093
C Blake Gilks
Chris D Bajdik
Christy Brookes
David G Huntsman
Forrest D Hsu
Heather N Andrews
Jill E Kucab
Joseph Ragaz
Leonard M Neckers
Nikita Makretsov
P304
P356
10.1158/0008-5472.CAN-03-1242
P407
P577
2004-01-01T00:00:00Z